CHAARTED: ADT Plus Docetaxel in Prostate Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.

Michael J. Morris, MD, member of the medical oncology and genitourinary oncology services at Memorial Sloan Kettering Cancer Center, was a discussant on the ECOG-led phase III randomized CHAARTED trial that studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.

Dr. Morris talks about side effects seen during the trial, what accounted for the increase in the time to development of castration resistance seen, as well as what he thinks the effect will be if results of the FIRSTANA trial show cabazitaxel to be superior to docetaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

Recent Videos
Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Related Content
Adding a focal boost to EBRT reduced the number of biochemical failures by more than 50%.

EBRT Plus Focal Boost Sustains Biochemical DFS Benefit in Prostate Cancer

Tim Cortese
October 9th 2025
Article

The 10-year biochemical DFS rate was 86% with EBRT plus focal boost vs 71% with standard EBRT in those with intermediate- and high-risk prostate cancer.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

Evaluating RLT-based combinations, RLTs across genitourinary cancers, and in earlier lines of therapy are among the considerations for further research.

How Will RLTs Be Integrated Into the Prostate Cancer Treatment Paradigm?

Roman Fabbricatore
October 5th 2025
Article

RLT-based combinations, RLTs across genitourinary cancers, and RLTs in earlier lines of therapy are among the considerations for further research.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Overall urinary toxicity was not significantly improved with SBRT vs moderately hypofractionated IMRT.

SBRT Reduces Bowel Toxicity vs IMRT in Intermediate-Risk Prostate Cancer

Tim Cortese
September 30th 2025
Article

SBRT achieved a 5-year DFS rate of 89% vs 92% with moderately hypofractionated IMRT in patients with intermediate-risk prostate cancer.

While metastasis-directed therapy has shown it may be a tool for prolonging PFS in other research, progression does still occur in most patients.

Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer

Tim Cortese
September 29th 2025
Article

The addition of 177Lu-PNT2002 did not significantly increase toxicity in patients with oligorecurrent prostate cancer who received SBRT.